期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血浆脂联素与2型糖尿病大血管并发症的关系 被引量：1

下载PDF
导出
摘要 目的观察2型糖尿病患者及糖尿病合并颈动脉增厚患者血浆脂联素水平的变化,探讨血浆脂联素与2型糖尿病大血管并发症的关系。方法选取2型糖尿病无颈动脉增厚患者61例及2型糖尿病合并颈动脉增厚患者37例,另选健康者30名作为对照组。测定受试者血浆脂联素水平、身高、体重等,比较脂联素水平的改变,以及与其他因素的相关性。结果2型糖尿病患者血浆脂联素水平低于健康对照组(P<0.01),糖尿病合并颈动脉增厚患者血浆脂联素水平又低于糖尿病无颈动脉增厚患者(P<0.01)。在受试者中,血浆脂联素与颈动脉内膜-中层厚度(IMT)、体重指数(BMI)呈负相关(P<0.01)。结论脂联素参与了糖尿病大血管病变的发生发展。如将血浆脂联素测定与颈动脉彩超结合应用,有助于早日诊断糖尿病大血管病变;提高血浆脂联素水平,为防治糖尿病大血管并发症提供新的途径。
作者 王淑珍 张合珍
机构地区 山西太原晋西机器工业集团有限责任公司医院
出处 《中西医结合心脑血管病杂志》 2009年第9期1112-1113,共2页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词 糖尿病 糖尿病大血管并发症 脂联素
分类号 R587.1 [医药卫生—内分泌] R255.4 [医药卫生—中医内科学]
  • 相关文献

参考文献6

  • 1潘云龙,朱妍,王晓玲,程英英,张真稳,王艳,陈晖.2型糖尿病患者血浆脂联素浓度改变及其与胰岛素抵抗的关系[J].实用临床医药杂志,2004,8(4):19-21. 被引量：21
  • 2谷卫,曾文衡,船桥通.2型糖尿病患者皮下、大网膜脂肪组织脂联素mRNA表达的定量研究[J].中华内分泌代谢杂志,2002,18(5):400-403. 被引量：30
  • 3Daimon M, Yamagtlchi H, Oizumi T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population[J]. Diabetes Care, 2003,26:2015 - 2020.
  • 4Diez J J, Iglesias P. The role of the novel adipoeyte - derived hormone adiponectin in human disease[J]. Eur J Endocrinol, 2003,148 (3) :293 - 300.
  • 5Hotta K , FunabashiT, AritaY, etal. Plasma concentrations of a novel, adipose - specific protein, adiponeetin, in type 2 diabetic patients[J]. Arterioscler Thromb Vasc Biol, 2000, 20 (6): 1595 - 1599.
  • 6Ouchi N , Kihai S , Arita Y , et al . Adiponectin , an adipocyte - derived plasma protein, inhibits endothelial NF-(Kappa) B signaling through a cAMP- dependent pathway[J]. Circulation, 2000, 102(11) :1296 - 1301.

二级参考文献19

  • 1李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量：2125
  • 2Yoda Murakami M, Taniguchi M, Takahashi K, et al. Chang in expression of GB28/adiponectin in carbon tetrachloride administrated mouse liver.Biochem Biophys Res Commun, 2001, 285: 372.
  • 3Nakano Y, Tobe T, Choi-Miura N H, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma[J]. J Biochem, 1996, 120: 803.
  • 4Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity[J]. Nat Med, 2001, 7: 941.
  • 5Hu E, Liang P, Spiegelman B M. AdipoQ is a novel adipose-specific gene dysregulated in obesity[J]. J Biol Chem. 1996 May 3, 271(18): 10697.
  • 6Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity[J]. Biochem Biophys Res Commun. 1999 Apr 2, 257(1): 79.
  • 7Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients[J]. Arterioscler Thromb Vasc Biol. 2000 Jun, 20(6): 1595.
  • 8Hotta K, Funahashi T, Bodkin N L, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys[J]. Diabetes, 2001 May, 50(5): 1126.
  • 9Yamamoto Y, Hirose H, Saito I, et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population[J]. Clin Sci (Lond). 2002 Aug, 103(2): 137.
  • 10Yang W S, Jeng C Y, Wu T J, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients[J]. Diabetes Care. 2002 Feb, 25(2): 376.

共引文献41

同被引文献23

  • 1Bolen S, Feldman L, Vassy J, et al. Systematic review : comparative effectiveness and safety of oral medications for type 2 diabetes mel- litus [ J ]. Ann Intern Med,2007,147 (6) :386-399.
  • 2Genuth S. The UKPDS and its global impact [J]. Diabet Med, 2008,25 Suppl 2:57-62.
  • 3Drab SR. Clinical studies of liraglutide ,a novel,once-daily human glu- cagon-like peptide-I analog for improved management of type 2 diabe- tes mellitus[ J]. Pharrnaeotherapy ,2009,29( 12 Pt 2) :43S-54S.
  • 4Vilsb~ll T. The effects of glueagon-like peptide-1 on the beta cell [J]. Diabetes Obes Metab ,2009,11 Suppl 3 : 1 l-18.
  • 5Iizuka K, Tomita R, Suwa T, et al. Normalization of fasting hyper- glycemia is beneficial for successful introduction of small amount of the GLP-1 analog liraglutide in an obese patient with type 2 diabe- tes mellitus [ J ]. Diabetol Int,2012,3 ( 1 ) :61-64.
  • 6Raun K, yon Voss P, Gotfredsen CF, et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed Rats, whereas a dipeptidyl peptidase-IVinhibitor, vildagliptin, does not [ J ]. Diabetes,2007,56 ( 1 ) : 8-15.
  • 7Inoue K, Maeda N, Kashine S, et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference : a pilot study of obese Japanese patients with type 2 diabetes [ J ]. Cardiovascu Diabeto1,2011,10 : 109.
  • 8Sowers JR. Endocrine functions of adipose tissue:focus on adipone- ctin [ J ]. Clin Cornerstone, 2008,9 ( 1 ) : 32 -38.
  • 9Okamoto M, Ohara-Imaizumo M, Kubota N, et al. Adiponectir induces insulin secretion in vitro and in vivo at a low glucose con- centration [J]. Diabetlogia,2008,51 ( 5 ) :827-835.
  • 10Lin P, Chen L, Li D, et al. Adiponectin reduces glucotoxicity- induced apoptosis of INS-1 rat insulin-secreting cells on a microflu- idic chip[ J]. Tohoku J Exp Med ,2009,217 (1) :59-65.

引证文献1

二级引证文献4

中西医结合心脑血管病杂志
2009年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部